UroGen Pharma Ltd.
Organization details
- Legal name
- UroGen Pharma Ltd.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Israel
- Headquarters city
- Ra'anana
- Headquarters country
- Israel
- Fiscal year end
- December
- Ticker symbol
- URGN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001668243
Board of directors
-
Arie Belldegrun · DirectorSince 2023
-
Cynthia M. Butitta · DirectorSince 2023
-
Daniel George Wildman · DirectorSince 2023
- Since 2023
-
James A. Robinson Jr. · DirectorSince 2023
-
Leana Wen · DirectorSince 2023
-
Ran Nussbaum · DirectorSince 2023
-
Stuart Holden · DirectorSince 2023
Director election results
Annual meeting of June 22, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
82.5%
-
93.2%
-
94.0%
-
98.4%
-
98.6%
Board connections
6 of this board's directors also sit on 13 other boards. 13 are in the same sector.
-
Allogene Therapeutics Inc. Same sectorvia Arie Belldegrun
- via Cynthia M. Butitta
-
CareDx Inc. Same sectorvia Fred E. Cohen
-
Century Therapeutics Inc. Same sectorvia Cynthia M. Butitta
-
Eledon Pharmaceuticals Inc. Same sectorvia James A. Robinson Jr.
-
Ginkgo Bioworks Holdings Inc. Same sectorvia Arie Belldegrun
-
Glaukos Corporation Same sectorvia Leana Wen
-
Intellia Therapeutics Inc. Same sectorvia Fred E. Cohen
-
Keros Therapeutics Inc. Same sectorvia Ran Nussbaum
-
Kyverna Therapeutics Inc. Same sectorvia Fred E. Cohen
-
LB Pharmaceuticals Inc Same sectorvia Ran Nussbaum
-
Olema Pharmaceuticals Inc. Same sectorvia Cynthia M. Butitta
-
Progyny Inc. Same sectorvia Fred E. Cohen
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $4,772,742
- 15 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 8, 2026 | Degnan Chris Officer (Chief Financial Officer) | Option exercise | +4,483 | — | — |
| Oct 8, 2026 | Degnan Chris Officer (Chief Financial Officer) | Open-market sale | −2,202 | $36.69 | $80,791 |
| Sep 8, 2026 | Schoenberg Mark Officer (Chief Medical Officer) | Open-market sale | −871 | $42.92 | $37,383 |
| Sep 8, 2026 | Smith Jason Drew Officer (General Counsel) | Open-market sale | −1,519 | $42.54 | $64,618 |
| Sep 7, 2026 | Schoenberg Mark Officer (Chief Medical Officer) | Option exercise | +1,667 | — | — |
| Sep 7, 2026 | Smith Jason Drew Officer (General Counsel) | Option exercise | +3,334 | — | — |
| Aug 26, 2026 | James A. Robinson Jr. Director | Option exercise | +2,000 | — | — |
| Aug 20, 2026 | Schoenberg Mark Officer (Chief Medical Officer) | Open-market sale | −60,677 | $47.05 | $2,854,853 |
| Jul 9, 2026 | Schoenberg Mark Officer (Chief Medical Officer) | Open-market sale | −10,000 | $40.00 | $400,000 |
| Jun 22, 2026 | Schoenberg Mark Officer (Chief Medical Officer) | Open-market sale | −10,000 | $35.01 | $350,100 |
| Jun 8, 2026 | Schoenberg Mark Officer (Chief Medical Officer) | Option exercise | +10,000 | — | — |
| Jun 8, 2026 | Schoenberg Mark Officer (Chief Medical Officer) | Open-market sale | −5,222 | $27.30 | $142,561 |
| May 26, 2026 | James A. Robinson Jr. Director | Option exercise | +2,000 | — | — |
| May 8, 2026 | Schoenberg Mark Officer (Chief Medical Officer) | Open-market sale | −10,000 | $30.00 | $300,000 |
| Feb 3, 2026 | Schoenberg Mark Officer (Chief Medical Officer) | Open-market sale | −1,844 | $19.69 | $36,308 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about UroGen Pharma Ltd.
How many directors are on UroGen Pharma Ltd.'s board?
UroGen Pharma Ltd.'s board has 8 directors: Arie Belldegrun, Cynthia M. Butitta, Daniel George Wildman, Fred E. Cohen, James A. Robinson Jr., Leana Wen, Ran Nussbaum and Stuart Holden.
Are UroGen Pharma Ltd. insiders buying or selling shares?
Over the last 12 months, UroGen Pharma Ltd. insiders made no open-market purchases and sold $4.8 million of shares in 15 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="urogen-pharma-ltd"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.